TRIM21 and systemic lupus erythematosus: The pathophysiologic mechanisms by which SLE and pSS patients have a greater risk of certain cancers have yet to be well understood, and the comprehension of the regulatory role of TRIM21/Ro52 in these diseases and malignancies remains partial.